Detalles de la búsqueda
1.
Cytomegalovirus antiviral resistance among participants in the phase 3 trial of letermovir vs valganciclovir prophylaxis in kidney transplant recipients.
J Infect Dis
; 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38853607
2.
Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
Antimicrob Agents Chemother
; 68(1): e0095323, 2024 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38047645
3.
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.
Infection
; 51(5): 1273-1284, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36648627
4.
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
JAMA
; 330(1): 33-42, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37279999
5.
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
Microbiol Spectr
; 12(3): e0356323, 2024 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38299867
6.
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Infect Dis Ther
; 12(12): 2725-2743, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37995070
7.
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.
NEJM Evid
; 1(2): EVIDoa2100043, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38319179
8.
Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial.
J Infect Dis
; 201(10): 1470-80, 2010 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20373959
9.
A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.
Antivir Ther
; 14(1): 111-5, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19320244
10.
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Infect Dis Ther
; 13(5): 1159-1160, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38662333
11.
Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity.
J Med Chem
; 45(14): 3143-60, 2002 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-12086500
12.
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.
J Med Chem
; 47(10): 2405-8, 2004 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-15115380
13.
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.
AIDS Res Hum Retroviruses
; 19(3): 177-86, 2003 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12689409
14.
Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
J Clin Virol
; 55(2): 134-9, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22824230
15.
Application of affinity selection-mass spectrometry assays to purification and affinity-based screening of the chemokine receptor CXCR4.
Comb Chem High Throughput Screen
; 15(6): 473-85, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22651846
16.
Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).
J Acquir Immune Defic Syndr
; 56(3): 222-9, 2011 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21209592
17.
Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor.
Virology
; 395(2): 268-79, 2009 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19846188
18.
Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.
Antimicrob Agents Chemother
; 49(12): 4911-9, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16304152
19.
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides.
Bioorg Med Chem Lett
; 13(3): 567-71, 2003 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-12565973
20.
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
J Virol
; 78(6): 2790-807, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-14990699